Sanofi Announces Closure of Cambridge Firm

Sanofi, a multinational pharmaceutical company headquartered in France, has announced the closure of Kymab’s Cambridge firm, axing ninety jobs.  

Sanofi purchased the antibody developer Kymab for just over $1 bn with an additional $350 million in potential achievements just under three years ago. The company has expressed its commitment to preserving as many positions as feasible.  

Kymab is a biopharmaceutical company focused on the discovery and development of innovative antibody-based therapeutics.  

A spokesperson for Sanofi explained, “To remain an agile and science-led company, Sanofi is continuously reviewing its R&D modalities to drive value and innovation for patients and deliver first and best in class medicines and vaccines.”  

They went on to add, “We will seek to employ as many of the impacted employees as possible within Sanofi.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.